Jemperli data create line of sight to organ-sparing in rectal cancer and beyond

Surgery may soon be displaced as standard of care for certain solid tumors with heavy DNA mutation burdens. New GSK data suggest that Jemperli’s exceptional, organ-preserving effects in rectal cancer are durable — and may extend to other cancer types — bringing the promise of replacing surgery with checkpoint inhibition closer to reality.

At the American Association for Cancer Research (AACR) annual meeting, GSK plc (LSE:GSK; NYSE:GSK) confirmed the benefits of Jemperli dostarlimab as neoadjuvant monotherapy in patients with DNA mismatch repair deficient (dMMR), locally advanced rectal cancers in an expanded study with extended follow-up. ...